This retrospective cohort study examined real-world treatment patterns for type 2 diabetes (T2D) patients initiating tirzepatide (Mounjaro) or semaglutide (Ozempic) from May 2022 to May 2023. The analysis utilized claims and laboratory data from the Healthcare Integrated Research Database. The study compared adherence, persistence, and treatment outcomes in patients stratified by prior GLP-1 RA exposure.
Key Clinical Findings
A total of 10,702 naive patient pairs and 5,577 non-naive patient pairs were included for analysis following propensity score matching. Results indicated that tirzepatide initiators exhibited higher adherence and persistence rates compared to semaglutide initiators, both in GLP-1 RA-naive and non-naive patient populations. A greater proportion of tirzepatide users achieved stringent A1c (less than 5.7%) and weight loss (greater than or equal to 15%) targets.
Tirzepatide was also associated with lower T2D-related pharmacy costs per responder when these stringent targets were achieved. Specifically, for A1c less than 5.7% and weight loss greater than or equal to 15%, tirzepatide demonstrated lower costs per responder compared to semaglutide. These findings suggest a potential clinical and economic advantage for tirzepatide in achieving significant treatment outcomes in real-world T2D management.